Stephen brings significant experience building early-stage life sciences companies. As the former Chief Medical Officer (CMO) and Head of R&D at Third Harmonic Bio, Stephen played a pivotal role driving the company's growth and securing critical financing.
Prior to his tenure at Third Harmonic Bio, Stephen served as the inaugural CMO of Regenxbio, where he navigated the company through a successful IPO, expanding its capabilities and advancing a pipeline focused on AAV gene therapies for retinal, metabolic, and neurodegenerative diseases.
Stephen's journey in life sciences began with clinical development roles at MedImmune/AstraZeneca and Abbott Labs, specializing in autoimmunity and inflammation research.
He earned his undergraduate degree from the University of California, Berkeley, and pursued his medical education at the David Geffen School of Medicine at UCLA. Following medical school, Stephen completed his preliminary year in Internal Medicine at the Washington Hospital Center before specializing in dermatology at the University of Texas Southwestern Medical School.
